JP2019530878A - 重篤患者における死亡率の予後診断に使用するためのバイオマーカー - Google Patents

重篤患者における死亡率の予後診断に使用するためのバイオマーカー Download PDF

Info

Publication number
JP2019530878A
JP2019530878A JP2019519961A JP2019519961A JP2019530878A JP 2019530878 A JP2019530878 A JP 2019530878A JP 2019519961 A JP2019519961 A JP 2019519961A JP 2019519961 A JP2019519961 A JP 2019519961A JP 2019530878 A JP2019530878 A JP 2019530878A
Authority
JP
Japan
Prior art keywords
patient
polynucleotide
biomarker
sepsis
mortality
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019519961A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019530878A5 (https=
Inventor
カトリ パーベシュ
カトリ パーベシュ
イー．スウィニー ティモシー
イー．スウィニー ティモシー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of JP2019530878A publication Critical patent/JP2019530878A/ja
Publication of JP2019530878A5 publication Critical patent/JP2019530878A5/ja
Priority to JP2022110659A priority Critical patent/JP2022153436A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
    • C40B40/08—Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/20—Polymerase chain reaction [PCR]; Primer or probe design; Probe optimisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2537/00—Reactions characterised by the reaction format or use of a specific feature
    • C12Q2537/10—Reactions characterised by the reaction format or use of a specific feature the purpose or use of
    • C12Q2537/165—Mathematical modelling, e.g. logarithm, ratio
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/20—Dermatological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medical Informatics (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
JP2019519961A 2016-06-26 2017-04-25 重篤患者における死亡率の予後診断に使用するためのバイオマーカー Pending JP2019530878A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022110659A JP2022153436A (ja) 2016-06-26 2022-07-08 重篤患者における死亡率の予後診断に使用するためのバイオマーカー

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662354789P 2016-06-26 2016-06-26
US62/354,789 2016-06-26
PCT/US2017/029468 WO2018004806A1 (en) 2016-06-26 2017-04-25 Biomarkers for use in prognosis of mortality in critically ill patients

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022110659A Division JP2022153436A (ja) 2016-06-26 2022-07-08 重篤患者における死亡率の予後診断に使用するためのバイオマーカー

Publications (2)

Publication Number Publication Date
JP2019530878A true JP2019530878A (ja) 2019-10-24
JP2019530878A5 JP2019530878A5 (https=) 2020-06-11

Family

ID=60786346

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019519961A Pending JP2019530878A (ja) 2016-06-26 2017-04-25 重篤患者における死亡率の予後診断に使用するためのバイオマーカー
JP2022110659A Pending JP2022153436A (ja) 2016-06-26 2022-07-08 重篤患者における死亡率の予後診断に使用するためのバイオマーカー

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022110659A Pending JP2022153436A (ja) 2016-06-26 2022-07-08 重篤患者における死亡率の予後診断に使用するためのバイオマーカー

Country Status (7)

Country Link
US (4) US10344332B2 (https=)
EP (1) EP3475473A4 (https=)
JP (2) JP2019530878A (https=)
CN (2) CN109451744B (https=)
AU (2) AU2017289600A1 (https=)
CA (1) CA3024724A1 (https=)
WO (1) WO2018004806A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023525489A (ja) * 2020-04-29 2023-06-16 インフラマティックス インコーポレイテッド ウイルス感染症を有する対象の死亡率リスクの決定

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018004806A1 (en) * 2016-06-26 2018-01-04 The Board Of Trustees Of The Leland Stanford Junior University Biomarkers for use in prognosis of mortality in critically ill patients
WO2018140256A1 (en) * 2017-01-17 2018-08-02 Duke University Gene expression signatures useful to predict or diagnose sepsis and methods of using the same
AU2019227186B2 (en) 2018-02-27 2025-07-10 The Board Of Trustees Of The Leland Stanford Junior University Classifier for identification of robust sepsis subtypes
AU2020244763A1 (en) * 2019-03-22 2021-09-30 Inflammatix, Inc. Systems and methods for deriving and optimizing classifiers from multiple datasets
JP2022530323A (ja) 2019-04-28 2022-06-29 ビスビュー メディカル，インコーポレイテッド デジタル検出能力および無線接続性を有する分子診断デバイス
EP4052042A1 (en) * 2019-10-28 2022-09-07 F. Hoffmann-La Roche AG Sepsis management
EP4217067A4 (en) * 2020-09-25 2025-02-12 The Board Of Trustees Of The Leland Stanford Junior University Method for determining a virally-infected subject's risk of developing severe symptoms
CN114606308A (zh) * 2022-01-26 2022-06-10 江门市中心医院 脓毒症ards的预后与治疗标志物

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050196817A1 (en) * 2004-01-20 2005-09-08 Molecular Staging Inc. Biomarkers for sepsis
US20090203534A1 (en) * 2005-10-21 2009-08-13 Hamid Hossain Expression profiles for predicting septic conditions
WO2012096245A1 (ja) * 2011-01-11 2012-07-19 三菱化学メディエンス株式会社 敗血症の予後の予測方法
JP2013527453A (ja) * 2010-05-17 2013-06-27 エフ．ホフマン−ラ ロシュ アーゲー 急性炎症における生存および回復を推定するためのｇｄｆ−１５に基づく手段および方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5245615A (en) 1991-06-06 1993-09-14 International Business Machines Corporation Diagnostic system and interface for a personal computer
EA001835B1 (ru) 1996-07-12 2001-08-27 Ферст Опинион Корпорейшн Автоматизированный способ диагностики (варианты)
WO2004044556A2 (en) * 2002-11-12 2004-05-27 Becton, Dickinson And Company Diagnosis of sepsis or sirs using biomarker profiles
CN101208602A (zh) * 2005-04-15 2008-06-25 贝克顿迪金森公司 脓毒症的诊断
US20090297474A1 (en) * 2005-11-25 2009-12-03 Dermot Kelleher Method for Detecting or Monitoring Sepsis by Analysing Cytokine mRNA Expression Levels
US20110312521A1 (en) * 2010-06-17 2011-12-22 Baylor Research Institute Genomic Transcriptional Analysis as a Tool for Identification of Pathogenic Diseases
US20120034214A1 (en) * 2010-07-22 2012-02-09 Isis Innovation Limited Methods and kits for determining the prognosis of pulmonary sarcoidosis
WO2012115885A1 (en) * 2011-02-22 2012-08-30 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Circulating biomarkers
US20150024969A1 (en) * 2011-09-12 2015-01-22 The Children's Mercy Hospital Sepsis prognosis biomarkers
US10190169B2 (en) 2013-06-20 2019-01-29 Immunexpress Pty Ltd Biomarker identification
EP3117030B1 (en) * 2014-03-14 2022-04-27 Hancock, Robert, E.W. Diagnostic for sepsis
WO2018004806A1 (en) * 2016-06-26 2018-01-04 The Board Of Trustees Of The Leland Stanford Junior University Biomarkers for use in prognosis of mortality in critically ill patients

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050196817A1 (en) * 2004-01-20 2005-09-08 Molecular Staging Inc. Biomarkers for sepsis
US20090203534A1 (en) * 2005-10-21 2009-08-13 Hamid Hossain Expression profiles for predicting septic conditions
JP2013527453A (ja) * 2010-05-17 2013-06-27 エフ．ホフマン−ラ ロシュ アーゲー 急性炎症における生存および回復を推定するためのｇｄｆ−１５に基づく手段および方法
WO2012096245A1 (ja) * 2011-01-11 2012-07-19 三菱化学メディエンス株式会社 敗血症の予後の予測方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PARNELL GRANT P. ET AL.: "IDENTIFYING KEY REGULATORY GENES IN THE WHOLE BLOOD OF SEPTIC PATIENTS TO MONITOR UNDERLYING IMMUNE", SHOCK, vol. 40, no. 3, JPN6021008733, 2013, pages 166 - 174, ISSN: 0004721769 *
TSALIK EPHRAIM L. ET AL.: "An integrated transcriptome and expressed variant analysis of sepsis survival and death", GENOME MEDICINE, vol. 6, no. 11, JPN6021008735, 2014, pages 111, ISSN: 0004462785 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023525489A (ja) * 2020-04-29 2023-06-16 インフラマティックス インコーポレイテッド ウイルス感染症を有する対象の死亡率リスクの決定

Also Published As

Publication number Publication date
US20190300959A1 (en) 2019-10-03
JP2022153436A (ja) 2022-10-12
AU2022211785A1 (en) 2022-08-25
US11608531B2 (en) 2023-03-21
EP3475473A4 (en) 2020-01-22
EP3475473A1 (en) 2019-05-01
AU2017289600A1 (en) 2018-12-06
CA3024724A1 (en) 2018-01-04
US10344332B2 (en) 2019-07-09
WO2018004806A1 (en) 2018-01-04
US20180274031A1 (en) 2018-09-27
US20190106750A1 (en) 2019-04-11
CN115161389A (zh) 2022-10-11
CN109451744B (zh) 2022-08-05
CN109451744A (zh) 2019-03-08
US20240011096A1 (en) 2024-01-11
US10648033B2 (en) 2020-05-12

Similar Documents

Publication Publication Date Title
JP7750895B2 (ja) 細菌感染及びウイルス感染を診断するための方法
US20240011096A1 (en) Biomarkers for use in prognosis of mortality in critically ill patients
JP6995622B2 (ja) 敗血症の診断法
EP3316875B1 (en) Methods to diagnose acute respiratory infections
EP3362579B1 (en) Methods for diagnosis of tuberculosis
WO2022235765A2 (en) Systems and methods for assessing a bacterial or viral status of a sample
WO2020096796A1 (en) Method for predicting severe dengue

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200417

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200417

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210304

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210316

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210611

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210914

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211026

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220125

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220308